Inhibition of androstenediol-dependent LNCaP tumour growth by 17α-ethynyl-5α-androstane-3α, 17Β-diol (HE3235)

British Journal of Cancer

Volumn 100, Issue 7, 2009, Pages 1068-1072

  Trauger, R ^a   Corey, E ^b   Bell, D ^c   White, S ^a   Garsd, A ^a   Stickney, D ^a   Reading, C ^a   Frincke, J ^a  

^a Hollis Eden Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ETHYNYL 5ALPHA ANDROSTANE 3ALPHA,17BETA DIOL; ANDROSTENEDIOL; ANDROSTENEDIOL DERIVATIVE; STEROID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TUMOR GROWTH;

ANDROSTANOLS; ANDROSTENEDIOL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 63849108231     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604987     Document Type: Article

References (19)

1. Bauer JA, Thompson TA, Church DR, Ariazi EA, Wilding G (2003) Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha, 24-dihydroxyvitamin D2. Prostate 55: 159-167
2. Cantor A (1997) Extending SAS Survival Analysis Techniques for Medical Research. SAS Institute Inc., pp 59-61
3. Chang HC, Miyamoto H, Marwah P, Lardy H, Yeh S, Huang KE, Chang C (1999) Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. Proc Natl Acad Sci USA 96: 11173-11177
4. Esquenet M, Swinnen JV, Heyns W, Verhoeven G (1996) Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha, 25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 28: 182-194
5. Fujii Y, Kawakami S, Okada Y, Kageyama Y, Kihara K (2004) Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells. Am J Physiol Endocrinol Metab 286: E927-E931
6. Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L (1998) Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. J Cell Biochem 69: 271-281
7. He D, Falany CN (2007) Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells. Prostate 67: 1318- 1329
8. Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52: 154 -179
9. Kruh J (1982) Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 42: 65-82
10. Maggiolini M, Recchia AG, Carpino A, Vivacqua A, Fasanella G, Rago V, Pezzi V, Briand PA, Picard D, Ando S (2004) Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. J Mol Endocrinol 32: 777-791
11. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C (1998) Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 95: 11083-11088
12. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M (2004) The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64: 765 -771
13. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD (2004) Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11: 459-476
14. StatXact (2004) Statistical software for exact nonparametric inference, User Manual (version 7). Cytel Software Corporation: Cambridge, MA, p 372
15. Suzuki K, Nishiyama T, Hara N, Yamana K, Takahashi K, Labrie F (2007) Importance of the intracrine metabolism of adrenal androgens in androgendependent prostate cancer. Prostate Cancer Prostatic Dis 10(3): 301-306
16. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398
17. Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J (2000) Involvement of p27Kip1 in G1 arrest by high dose 5 alphadihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 19: 670-679
18. Walls R, Thibault A, Liu L, Wood C, Kozlowski JM, Figg WD, Sampson ML, Elin RJ, Samid D (1996) The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. Prostate 29: 177-182
19. Westfall PH (1999) Multiple comparisons and multiple tests. SAS Institute Inc.: Cary, NC, USA, pp 29- 30